Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population
These results provide early experience of aflibercept 8 mg in a clinical cohort in hard-to-treat patients. The current analysis demonstrated favorable anatomical outcomes after switching in most patients, with no safety signals.
Authors
- Chui Ming Gemmy Cheung
- Kelvin Y. C. Teo
- Wataru Kikushima
Institutions
- The University of Sydney (AU)
- SingHealth (SG)
- Singapore National Eye Center (SG)
- Singapore Eye Research Institute (SG)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1007/s40123-026-01323-2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Research Council
- National Medical Research Council